William Freeman, M.D.
University of California,
San Diego, CA
$106,000
Dr. Freeman’s clinical center serves as a site in the Foundation’s clinical trial network for the evaluation of potential treatments and cures for retinal degenerations.
PRE-CLINICAL ASSESSMENT CENTER
Gustavo Aguirre, VMD, Ph.D.
University of Pennsylvania
Philadelphia, PA
$30,512
Dr. Aguirre evaluated the neuroprotective effects of a compound developed by EyeCyte Therapeutics in a dog model of cone dystrophy.
Bärbel Rohrer, Ph.D.
Medical University of
South Carolina,
Charleston, SC
$80,000
Rong Wen, M.D., Ph.D.
University of Pennsylvania,
Philadelphia, PA
$80,000
Drs. Rohrer and Wen conducted laboratory studies of compounds and molecules which hold potential for being treatments for retinal degenerations.
FOUNDATION FIGHTING BLINDNESS CLINICAL RESEARCH INSTITUTE
PRE-CLINICAL SUPPORT
Martha Neuringer, PhD
Oregon Health Science Center
Portland, OR
$65,358
CLINICAL SUPPORT
Hendrik Scholl, M.D., M.A.
Johns Hopkins University School of Medicine
Baltimore, MD
Translational Research Acceleration Program
$15,000
Dr. Scholl is serving as the principal investigator for ProgStar, a natural history study of people with Stargardt disease. The goals of the study include determination of endpoints and identification of participants for future clinical trials.
Oxford BioMedica
José-Alain Sahel, MD, PhD
INSERM, Hôpital Saint-Antoine,
Hôpital des Quinze-Vingts, UCL,
Paris, France
$125,000
CAREER DEVELOPMENT AWARD
Enhanced Career Development Award
Hendrik Scholl, M.D., M.A.
Johns Hopkins University School of Medicine
Baltimore, MD
Translational Research Acceleration Program
$170,000
Dr. Scholl is evaluating state-of-the-art imaging technologies to quickly and effectively measure the effect of potential retinal disease treatments in clinical trials. Images from these technologies may be used as endpoints in future human studies.
CLINICAL TRIAL
Foundation Fighting Blindness Clinical Research Institute
Columbia, MD
$1,445,751
A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Retinitis Pigmentosa
MEETINGS AND WORKSHOPS
Optogenetics Therapies for Vision
Boston, MA
Translation Research Acceleration Program
$50,000
